Enzo Biochem Total Assets 2010-2022 | ENZ

Enzo Biochem total assets from 2010 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Enzo Biochem Annual Total Assets
(Millions of US $)
2021 $114
2020 $113
2019 $107
2018 $102
2017 $108
2016 $112
2015 $68
2014 $64
2013 $59
2012 $69
2011 $109
2010 $115
2009 $133
Enzo Biochem Quarterly Total Assets
(Millions of US $)
2022-04-30 $104
2022-01-31 $109
2021-10-31 $108
2021-07-31 $114
2021-04-30 $114
2021-01-31 $112
2020-10-31 $114
2020-07-31 $113
2020-04-30 $116
2020-01-31 $117
2019-10-31 $125
2019-07-31 $107
2019-04-30 $111
2019-01-31 $89
2018-10-31 $94
2018-07-31 $102
2018-04-30 $105
2018-01-31 $108
2017-10-31 $109
2017-07-31 $108
2017-04-30 $107
2017-01-31 $106
2016-10-31 $110
2016-07-31 $112
2016-04-30 $76
2016-01-31 $81
2015-10-31 $74
2015-07-31 $68
2015-04-30 $59
2015-01-31 $60
2014-10-31 $63
2014-07-31 $64
2014-04-30 $63
2014-01-31 $56
2013-10-31 $58
2013-07-31 $59
2013-04-30 $58
2013-01-31 $62
2012-10-31 $67
2012-07-31 $69
2012-04-30 $96
2012-01-31 $99
2011-10-31 $104
2011-07-31 $109
2011-04-30 $110
2011-01-31 $111
2010-10-31 $115
2010-07-31 $115
2010-04-30 $116
2010-01-31 $127
2009-10-31 $132
2009-07-31 $133
2009-04-30 $138
2009-01-31 $140
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.105B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.984B 9.16
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.873B 0.00
QIAGEN (QGEN) Netherlands $9.383B 15.71
Ginkgo Bioworks Holdings (DNA) United States $4.998B 0.00
Arcus Biosciences (RCUS) United States $1.819B 35.51
Myovant Sciences (MYOV) United Kingdom $1.614B 0.00
Emergent Biosolutions (EBS) United States $1.040B 6.03
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.305B 0.00
Gelesis Holdings (GLS) United States $0.081B 0.00
SQZ Biotechnologies (SQZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00